Do you want to read an article? Please log in or register.
Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study
Inflammatory Bowel Disease
Indications
Related content
Inflammatory Bowel Disease
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study
Adv Ther
Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, de Barba C, Maconi G, Cataletti G, Scaldaferri F, Napolitano D, Costa F, Ceccarelli L, Marzo M, Monterubbianesi R, di Fonzo M, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodino' S, Sebkova L, Bodini G, Pranzo G, Serio M, Scarcelli A, Luppino I, Ferronato A, Spagnuolo R, Luzza F, Morano D, Gravina AG, Pellegrino R, Vespere G, Sedda S, Allegretta L, Fanigliulo L, Grossi L, Cortellini F, Forti G, Neve V, Piergallini S, Scarozza P, Bevevino G, Iacopini F, Capone P, Gaiani F, Kayali S, Mucherino C, D'antonio E, D'ascoli B, Colucci R, Bachetti F, Giorgetti GM, Clemente V, Pagnini C, Cuomo A, Donnarumma L, Onidi FM, Satta PU, Picchio M, Papa A, Italian Network for Inflammatory Bowel Diseases (IN-IBD)
doi: 10.1007/s12325-026-03622-3
Inflammatory Bowel Disease
Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study
J Crohns Colitis
Privitera G, Bezzio C, Buono AD, Gabbiadini R, Loy L, Ranucci L, Bertin L, Masoni B, Migliorisi G, Sauta E, Delleani M, Savevski V, Porta MD, D'amico S, Armuzzi A
doi: 10.1093/ecco-jcc/jjaf239
Inflammatory Bowel Disease
Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
Inflamm Bowel Dis
Ünal NG, Bakkaloğlu OK, Kav T, Eşkazan T, Kani HT, Akpınar A, Akıncıoğlu P, Dağcı G, Şendur İ, Büyüktorun İ, Barutçu S, Kılıç G, Bengi G, Çavuş B, Oruç N, Alahdab YÖ, Atuğ Ö, Dinçer D, Karakan T, Hatemi Aİ, Erzin YZ, Tezel A, Törüner M, Akyüz F, Çelik AF
doi: 10.1093/ibd/izag126
Inflammatory Bowel Disease
Etrasimod as induction and maintenance treatment for patients with moderately to severely active ulcerative colitis in East Asia (ENLIGHT UC): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
Lancet Gastroenterol Hepatol
Wu K, Zheng C, Cao Q, Ding Y, Gao X, Zhong J, Chiu CT, Zhang H, Wang X, Wang B, Liang J, Liu X, Zhou Y, Xu B, Kim TO, Shen X, Chen D, Chen W, Liu Y, Shen J, Liu F, Ding X, Zhan Q, Chou JW, Zeng S, Lin Y, Ying L, Chen X, ENLIGHT UC Study Group
doi: 10.1016/S2468-1253(25)00198-0
Inflammatory Bowel Disease
Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study)
Inflamm Bowel Dis
Lin SH, Kuo CJ, Chuang CH, Chang CW, Chung CS, Chou JW, Huang TY, Yen HH, Tsai TJ, Lin CP, Chang CH, Tai CM, Tai WC, Yao CC, Chen CC, Pan YB, Le PH
doi: 10.1093/ibd/izag150
Inflammatory Bowel Disease
Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: the miri real multicenter study
J Crohns Colitis
D'Amico F, Fanizzi F, Dal Buono A, Gabbiadini R, Nardone OM, Zilli A, Allocca M, Lauriola GM, Jairath V, Peyrin-Biroulet L, Fiorino G, Castiglione F, Massimino L, Mastronardi M, Armuzzi A, Danese S
doi: 10.1093/ecco-jcc/jjag062
Inflammatory Bowel Disease
Upadacitinib Maintenance Therapy in Pediatric Ulcerative Colitis: 52-week Multicenter Study from the Porto Group of ESPGHAN
Clin Gastroenterol Hepatol
Yerushalmy-Feler A, Spencer EA, Dubinsky MC, Suskind DL, Mitrova K, Hradsky O, Conrad MA, Kelsen JR, Sladek M, Yeh PJ, Tzivinikos C, Henderson P, Wlazlo M, Hackl L, Shouval DS, Mouratidou N, Bramuzzo M, Urlep D, Olbjørn C, Mancuso G, Schneider AM, Pujol-Muncunill G, Yogev D, Kang B, Gasparetto M, Rungø C, Romano C, Martinelli M, Kolho KL, Hojsak I, Norsa L, Rinawi F, Sansotta N, Rimon RM, Granot M, Scarallo L, Trindade E, Rodríguez-Belvís MV, Turner D, Cohen S
doi: 10.1016/j.cgh.2026.02.012
Inflammatory Bowel Disease
Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis with Severe Endoscopic Disease
Am J Gastroenterol
Wong ECL, Jairath V, Dulai PS, Marshall JK, Ma C, Reinisch W, Narula N
doi: 10.14309/ajg.0000000000003940
Inflammatory Bowel Disease
Efficacy, Safety, and Pharmacokinetics of Upadacitinib Among Patients in East Asia With Moderately to Severely Active Ulcerative Colitis: A Post Hoc Subanalysis of Randomized Phase 3 Studies
J Gastroenterol Hepatol
Wei SC, Nakase H, Ye BD, Chao K, Wu HY, Eccleston J, Yao X, Palac H, Mohamed MF, Ponce-Bobadilla AV, Suravaram S, Barrachina EM, Hisamatsu T, Gao X
doi: 10.1111/jgh.70634